RT @jitcancer: #ICYMI - Popular #JITC Review: Consensus disease definitions for neurologic immune-related adverse events of immune checkpoi…
RT @jitcancer: #ICYMI - Popular #JITC Review: Consensus disease definitions for neurologic immune-related adverse events of immune checkpoi…
#ICYMI - Popular #JITC Review: Consensus disease definitions for neurologic immune-related adverse events of immune checkpoint inhibitors https://t.co/F3ozIGIr66 @kreynoldsMD https://t.co/68E58hzDhZ
RT @MGHNeurology: Using a Delphi process, 28 researchers from 17 institutions have now published “Consensus disease definitions for neurolo…
RT @jitcancer: New #JITC article: Consensus disease definitions for neurologic immune-related adverse events of immune checkpoint inhibitor…
RT @MGHNeurology: Using a Delphi process, 28 researchers from 17 institutions have now published “Consensus disease definitions for neurolo…
Consensus disease definitions for neurologic immune-related adverse events of immune checkpoint inhibitors https://t.co/Syg8ZKAsOt
RT @jitcancer: New #JITC article: Consensus disease definitions for neurologic immune-related adverse events of immune checkpoint inhibitor…
Consensus disease definitions for neurologic immune-related adverse events of immune checkpoint inhibitors. https://t.co/h9AtaanaA9 https://t.co/f5qnhPn9vl
RT @MGHNeurology: Using a Delphi process, 28 researchers from 17 institutions have now published “Consensus disease definitions for neurolo…
RT @MGHNeurology: Using a Delphi process, 28 researchers from 17 institutions have now published “Consensus disease definitions for neurolo…
Using a Delphi process, 28 researchers from 17 institutions have now published “Consensus disease definitions for neurologic immune-related adverse events of immune checkpoint inhibitors,” which will help guide prompt diagnosis, tracking and treatment: htt
RT @ProjDataSphere: Proud to be part of this publication @jitcancer to aid diagnosis and treatment of neurological side effects in cancer p…
RT @StaceyLClardy: Proud to have been involved in a very small way in this much needed consensus paper on neurologic presentations of check…
RT @mlage: It was a pleasure and I learned a lot working with this wonderful diverse group of individuals, bringing the #pathologist #neuro…
RT @jitcancer: New #JITC article: Consensus disease definitions for neurologic immune-related adverse events of immune checkpoint inhibitor…
RT @jitcancer: New #JITC article: Consensus disease definitions for neurologic immune-related adverse events of immune checkpoint inhibitor…
RT @mlage: It was a pleasure and I learned a lot working with this wonderful diverse group of individuals, bringing the #pathologist #neuro…
RT @mlage: It was a pleasure and I learned a lot working with this wonderful diverse group of individuals, bringing the #pathologist #neuro…
RT @mlage: It was a pleasure and I learned a lot working with this wonderful diverse group of individuals, bringing the #pathologist #neuro…
It was a pleasure and I learned a lot working with this wonderful diverse group of individuals, bringing the #pathologist #neuropath perspective. We are very much part of the care team, and progress is built by working together! @MGHPathology @MGHCancer
RT @jitcancer: New #JITC article: Consensus disease definitions for neurologic immune-related adverse events of immune checkpoint inhibitor…
RT @StaceyLClardy: Proud to have been involved in a very small way in this much needed consensus paper on neurologic presentations of check…
RT @StaceyLClardy: Proud to have been involved in a very small way in this much needed consensus paper on neurologic presentations of check…
RT @jitcancer: New #JITC article: Consensus disease definitions for neurologic immune-related adverse events of immune checkpoint inhibitor…
Proud to have been involved in a very small way in this much needed consensus paper on neurologic presentations of checkpoint inhibitor-related AEs — well done, Dr. Amanda Guidon and colleagues! 👏🏼🧠@harvardneuromds @MGHNeurology
Proud to be part of this publication @jitcancer to aid diagnosis and treatment of neurological side effects in cancer patients receiving immunotherapy. #immunecheckpointinhibitor #oncology
RT @DrJNaidoo: Great to be a part of this multicenter project including @HopkinsThoracic to create consensus definitions for neurologic tox…
RT @jitcancer: New #JITC article: Consensus disease definitions for neurologic immune-related adverse events of immune checkpoint inhibitor…
RT @DrJNaidoo: Great to be a part of this multicenter project including @HopkinsThoracic to create consensus definitions for neurologic tox…
RT @DrJNaidoo: Great to be a part of this multicenter project including @HopkinsThoracic to create consensus definitions for neurologic tox…
RT @jitcancer: New #JITC article: Consensus disease definitions for neurologic immune-related adverse events of immune checkpoint inhibitor…
RT @jitcancer: New #JITC article: Consensus disease definitions for neurologic immune-related adverse events of immune checkpoint inhibitor…
Great to be a part of this multicenter project including @HopkinsThoracic to create consensus definitions for neurologic toxicities from immunotherapy Led by Amanda Guidon & @kreynoldsMD @MGHCancerCenter
RT @jitcancer: New #JITC article: Consensus disease definitions for neurologic immune-related adverse events of immune checkpoint inhibitor…
RT @jitcancer: New #JITC article: Consensus disease definitions for neurologic immune-related adverse events of immune checkpoint inhibitor…
RT @jitcancer: New #JITC article: Consensus disease definitions for neurologic immune-related adverse events of immune checkpoint inhibitor…
New #JITC article: Consensus disease definitions for neurologic immune-related adverse events of immune checkpoint inhibitors @TomasNeilan @DrJNaidoo @BSantomasso @kreynoldsMD https://t.co/WOvyF3JEDC https://t.co/vEBMSyfJkO
RT @DrJNaidoo: Neuro irAEs from ICIs @jitcancer 27 panelists (15 academic centers) created criteria via modified delphi to define: - n-irA…
Valuable and timely work about neurologic immune related AEs ! #Immunotherapy @OncoViews @OncoAlert
Proud to contribute to this effort led by @kreynoldsMD and the team at @MGHMedicine!
RT @DrJNaidoo: Neuro irAEs from ICIs @jitcancer 27 panelists (15 academic centers) created criteria via modified delphi to define: - n-irA…
RT @DrJNaidoo: Neuro irAEs from ICIs @jitcancer 27 panelists (15 academic centers) created criteria via modified delphi to define: - n-irA…
RT @DrJNaidoo: Neuro irAEs from ICIs @jitcancer 27 panelists (15 academic centers) created criteria via modified delphi to define: - n-irA…
RT @DrJNaidoo: Neuro irAEs from ICIs @jitcancer 27 panelists (15 academic centers) created criteria via modified delphi to define: - n-irA…
RT @DrJNaidoo: Neuro irAEs from ICIs @jitcancer 27 panelists (15 academic centers) created criteria via modified delphi to define: - n-irA…
Neuro irAEs from ICIs @jitcancer 27 panelists (15 academic centers) created criteria via modified delphi to define: - n-irAE subtype, severity, autoab assocn - irMeningitis, irEncephalitis, irDemyelinating dx, irVasculitis, irNeuropathy, irNMJ, irMyopathy
New 3i Investigator Article Alert!! Consensus disease definitions for neurologic immune-related adverse events of immune checkpoint inhibitors https://t.co/zdFR1noAmf #sciencetwitter #academictwitter
A new #COVID19 publication from @UUtah researchers! Check it out: Consensus disease definitions for neurologic immune-related adverse events of immune checkpoint inhibitors https://t.co/gHC0UnS9hc @uofuresearch @uuhsresearch
Consensus disease definitions for neurologic immune-related adverse events of immune checkpoint inhibitors https://t.co/dSbfTLUx9k